Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.

Hollis RL, Stanley B, Iida Y, Thomson J, Churchman M, Rye T, Mackean M, Nussey F, Gourley C, Herrington CS.

Gynecol Oncol. 2019 Sep 5. pii: S0090-8258(19)31487-8. doi: 10.1016/j.ygyno.2019.09.001. [Epub ahead of print]

2.

High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.

Hollis RL, Churchman M, Michie CO, Rye T, Knight L, McCavigan A, Perren T, Williams ARW, McCluggage WG, Kaplan RS, Jayson GC, Oza A, Harkin DP, Herrington CS, Kennedy R, Gourley C.

Cancer. 2019 Aug 15;125(16):2772-2781. doi: 10.1002/cncr.32079. Epub 2019 Jun 2.

3.

Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse.

Hollis RL, Carmichael J, Meynert AM, Churchman M, Hallas-Potts A, Rye T, MacKean M, Nussey F, Semple CA, Herrington CS, Gourley C.

Am J Obstet Gynecol. 2019 Sep;221(3):245.e1-245.e15. doi: 10.1016/j.ajog.2019.04.035. Epub 2019 May 2.

4.

Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.

Stanley B, Hollis RL, Nunes H, Towler JD, Yan X, Rye T, Dawson C, Mackean MJ, Nussey F, Churchman M, Herrington CS, Gourley C.

Gynecol Oncol. 2019 Feb;152(2):278-285. doi: 10.1016/j.ygyno.2018.11.030. Epub 2018 Nov 28.

PMID:
30501904
5.

Diurnal profile of interstitial glucose following dexamethasone prophylaxis for chemotherapy treatment of gynaecological cancer.

Lyall MJ, Thethy I, Steven L, MacKean M, Nussey F, Sakala M, Rye T, Strachan MWJ, Dover AR.

Diabet Med. 2018 Nov;35(11):1508-1514. doi: 10.1111/dme.13770. Epub 2018 Aug 3.

PMID:
29938852
6.

Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment.

Xintaropoulou C, Ward C, Wise A, Queckborner S, Turnbull A, Michie CO, Williams ARW, Rye T, Gourley C, Langdon SP.

BMC Cancer. 2018 Jun 5;18(1):636. doi: 10.1186/s12885-018-4521-4.

7.

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.

Hollis RL, Meynert AM, Churchman M, Rye T, Mackean M, Nussey F, Arends MJ, Sims AH, Semple CA, Herrington CS, Gourley C.

BMC Cancer. 2018 Jan 3;18(1):16. doi: 10.1186/s12885-017-3981-2.

8.

Direct coupling of electromembrane extraction to mass spectrometry - Advancing the probe functionality toward measurements of zwitterionic drug metabolites.

Rye TK, Fuchs D, Pedersen-Bjergaard S, Petersen NJ.

Anal Chim Acta. 2017 Aug 29;983:121-129. doi: 10.1016/j.aca.2017.05.038. Epub 2017 Jun 19.

PMID:
28811018
9.

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.

Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.

Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.

10.

Higher incidence of isolated brain metastases in ovarian cancer patients with previous early breast cancer.

Faluyi OO, Gourley C, Smyth JF, Faratian D, Williams AR, Rye T, Rye R, Stewart M, Mackean MJ.

Int J Gynecol Cancer. 2010 Dec;20(9):1511-7.

PMID:
21370594
11.

Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype.

Gourley C, Michie CO, Roxburgh P, Yap TA, Harden S, Paul J, Ragupathy K, Todd R, Petty R, Reed N, Hayward RL, Mitchell P, Rye T, Schellens JH, Lubinski J, Carmichael J, Kaye SB, Mackean M, Ferguson M.

J Clin Oncol. 2010 May 20;28(15):2505-11. doi: 10.1200/JCO.2009.25.1082. Epub 2010 Apr 20.

PMID:
20406939
12.

Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.

Storey DJ, Rush R, Stewart M, Rye T, Al-Nafussi A, Williams AR, Smyth JF, Gabra H.

Cancer. 2008 May 15;112(10):2211-20. doi: 10.1002/cncr.23438.

13.

Validation of a new prognostic index for advanced epithelial ovarian cancer: results from its application to a UK-based cohort.

Clark TG, Stewart M, Rye T, Smyth JF, Gourley C.

J Clin Oncol. 2007 Dec 10;25(35):5669-70; author reply 5670-1. No abstract available.

PMID:
18065745
14.

Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.

Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams AR, Nafussi AA, Rye T, Rye R, Stewart M, McCurdy J, Mano M, Reed N, McMahon T, Vasey P, Gabra H, Langdon SP.

Clin Cancer Res. 2007 Jun 15;13(12):3617-22.

15.

Carcinosarcoma of the ovary: 19 years of prospective data from a single center.

Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, Bradburn M, Smyth J, Gabra H.

Cancer. 2004 May 15;100(10):2148-53.

16.

Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study.

Bowman A, Rye T, Ross G, Wheatley A, Smyth JF.

J Clin Oncol. 2001 Jul 1;19(13):3255-9.

PMID:
11432893
17.

Forging computer links when you have no tools.

Rye T, Spiegel E, Perrin R, Meyer D.

Mater Manag Health Care. 1992 Mar;1(1):32-5.

PMID:
10125477
18.

Effect of baclofen on tardive dyskinesia.

Gerlach J, Rye T, Kristjansen P.

Psychopharmacology (Berl). 1978 Mar 1;56(2):145-51.

PMID:
417365

Supplemental Content

Support Center